Culture and Real-time Polymerase Chain reaction sensitivity in the diagnosis of invasive meningococcal disease: Does culture miss less severe cases?


Journal

PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081

Informations de publication

Date de publication:
2019
Historique:
received: 10 08 2018
accepted: 12 02 2019
entrez: 14 3 2019
pubmed: 14 3 2019
medline: 28 11 2019
Statut: epublish

Résumé

Invasive meningococcal disease (IMD) is a highly lethal disease. Diagnosis is commonly performed by culture or Realtime-PCR (qPCR). Our aim was to evaluate, retrospectively, whether culture positivity correlates with higher bacterial load and fatal outcome. Our secondary aim was to compare culture and qPCR sensitivity. The National Register for Molecular Surveillance was used as data source. Cycle threshold (CT), known to be inversely correlated with bacterial load, was used to compare bacterial load in different samples. Three-hundred-thirteen patients were found positive for Neisseria meningitidis by qPCR, or culture, or both; 41 died (case fatality rate 13.1%); 128/143 (89.5%) blood samples and 138/144 (95.8%) CSF were positive by qPCR, 37/143 (25.9%) blood samples and 45/144 (31.2%) CSF were also positive in culture. qPCR was 3.5 times (blood) or 3.1 times (CSF) more sensitive than culture in achieving a laboratory diagnosis of IMD (OR 24.4; 95% CI 12.2-49.8; p < .10-4; Cohen's κ 0.08 for blood and OR 49.0; 95% CI 19.1-133.4; p<10-4; Cohen's κ 0.02; for CSF). Positivity of culture did not correlate with higher bacterial loads in blood (mean CT 27.7±5.71, and CT 28.1±6.03, p = 0.739 respectively in culture positive or negative samples) or in CSF (mean CT 23.1±4.9 and 24.7±5.4 respectively in positive or negative CSF samples, p = 0.11).CT values in blood from patients who died were significantly lower than in patients who survived (respectively mean 18.0, range 14-23 and mean 29.6, range 16-39; p<10-17). No deaths occurred in patients with CT in blood over 23. Positive blood cultures were found in 10/25 (40%) patients who died and in 32/163 (19.6%) patients who survived, p = 0.036, OR 2.73; 95% CL 1.025-7.215), however 60% of deaths would have remained undiagnosed with the use of culture only. In conclusion our study demonstrated that qPCR is significantly (at least 3 times) more sensitive than culture in the laboratory confirmation of IMD. The study also demonstrated that culture negativity is not associated with lower bacterial loads and with less severe cases. On the other side, in patients with sepsis, qPCR can predict fatal outcome since higher bacterial load, evaluated by qPCR, appears strictly associated with most severe cases and fatal outcome. The study also showed that molecular techniques such as qPCR can provide a valuable addition to the proportion of diagnosed and serotyped cases of IMD.

Sections du résumé

BACKGROUND
Invasive meningococcal disease (IMD) is a highly lethal disease. Diagnosis is commonly performed by culture or Realtime-PCR (qPCR).
AIMS
Our aim was to evaluate, retrospectively, whether culture positivity correlates with higher bacterial load and fatal outcome. Our secondary aim was to compare culture and qPCR sensitivity.
METHODS
The National Register for Molecular Surveillance was used as data source. Cycle threshold (CT), known to be inversely correlated with bacterial load, was used to compare bacterial load in different samples.
RESULTS
Three-hundred-thirteen patients were found positive for Neisseria meningitidis by qPCR, or culture, or both; 41 died (case fatality rate 13.1%); 128/143 (89.5%) blood samples and 138/144 (95.8%) CSF were positive by qPCR, 37/143 (25.9%) blood samples and 45/144 (31.2%) CSF were also positive in culture. qPCR was 3.5 times (blood) or 3.1 times (CSF) more sensitive than culture in achieving a laboratory diagnosis of IMD (OR 24.4; 95% CI 12.2-49.8; p < .10-4; Cohen's κ 0.08 for blood and OR 49.0; 95% CI 19.1-133.4; p<10-4; Cohen's κ 0.02; for CSF). Positivity of culture did not correlate with higher bacterial loads in blood (mean CT 27.7±5.71, and CT 28.1±6.03, p = 0.739 respectively in culture positive or negative samples) or in CSF (mean CT 23.1±4.9 and 24.7±5.4 respectively in positive or negative CSF samples, p = 0.11).CT values in blood from patients who died were significantly lower than in patients who survived (respectively mean 18.0, range 14-23 and mean 29.6, range 16-39; p<10-17). No deaths occurred in patients with CT in blood over 23. Positive blood cultures were found in 10/25 (40%) patients who died and in 32/163 (19.6%) patients who survived, p = 0.036, OR 2.73; 95% CL 1.025-7.215), however 60% of deaths would have remained undiagnosed with the use of culture only.
CONCLUSIONS
In conclusion our study demonstrated that qPCR is significantly (at least 3 times) more sensitive than culture in the laboratory confirmation of IMD. The study also demonstrated that culture negativity is not associated with lower bacterial loads and with less severe cases. On the other side, in patients with sepsis, qPCR can predict fatal outcome since higher bacterial load, evaluated by qPCR, appears strictly associated with most severe cases and fatal outcome. The study also showed that molecular techniques such as qPCR can provide a valuable addition to the proportion of diagnosed and serotyped cases of IMD.

Identifiants

pubmed: 30865671
doi: 10.1371/journal.pone.0212922
pii: PONE-D-18-23624
pmc: PMC6415896
doi:

Substances chimiques

DNA, Bacterial 0

Types de publication

Comparative Study Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0212922

Déclaration de conflit d'intérêts

SG received a scholarship from GSK for meningococcal epidemiology; GSK did not participate in study design, data analysis, manuscript writing and in any other aspects related to the present work. This does not alter our adherence to PLOS ONE policies on sharing data and materials. The authors have no other conflict of interest.

Références

Int J Microbiol. 2016;2016:4197187
pubmed: 27563310
Mol Diagn Ther. 2011 Apr 1;15(2):109-13
pubmed: 21452905
Clin Infect Dis. 2009 Mar 1;48(5):587-94
pubmed: 19191644
Commun Dis Intell Q Rep. 2012 Mar 31;36(1):1-69
pubmed: 23153082
Clin Infect Dis. 2010 Nov 1;51(9):1042-9
pubmed: 20883110
N Engl J Med. 2006 Oct 19;355(16):1699-713
pubmed: 17050894
N Engl J Med. 2001 May 3;344(18):1378-88
pubmed: 11333996
PLoS One. 2015 Mar 23;10(3):e0120757
pubmed: 25798599
Am J Trop Med Hyg. 2009 Sep;81(3):475-83
pubmed: 19706918
Vaccine. 2014 Feb 26;32(10):1187-91
pubmed: 24120548
Clin Ther. 2009 Jun;31(6):1266-73
pubmed: 19695393
Pediatr Crit Care Med. 2005 May;6(3 Suppl):S14-8
pubmed: 15857548
J Infect. 2016 Nov;73(5):427-436
pubmed: 27475788
Emerg Infect Dis. 2016 Mar;22(3):469-75
pubmed: 26890305
Arch Dis Child. 2002 Jan;86(1):44-6
pubmed: 11806883
Iran J Microbiol. 2010 Jun;2(2):73-9
pubmed: 22347552
FEMS Immunol Med Microbiol. 2003 Oct 24;39(1):31-6
pubmed: 14556993
Pediatrics. 2001 Nov;108(5):1169-74
pubmed: 11694698
J Infect. 2013 Nov;67(5):385-90
pubmed: 23796865
PLoS One. 2011 May 05;6(5):e19361
pubmed: 21573213
Pediatr Infect Dis J. 2007 May;26(5):416-22
pubmed: 17468652
PLoS One. 2010 Feb 19;5(2):e9282
pubmed: 20174571

Auteurs

Sara Guiducci (S)

Department of Health Sciences, Section of Pediatrics, University of Florence, Florence, Italy.
Pediatric Clinic 2, Pediatric Immunology, Meyer Children's Hospital, Florence, Italy.

Maria Moriondo (M)

Department of Health Sciences, Section of Pediatrics, University of Florence, Florence, Italy.

Francesco Nieddu (F)

Department of Health Sciences, Section of Pediatrics, University of Florence, Florence, Italy.
Pediatric Clinic 2, Pediatric Immunology, Meyer Children's Hospital, Florence, Italy.

Silvia Ricci (S)

Department of Health Sciences, Section of Pediatrics, University of Florence, Florence, Italy.
Pediatric Clinic 2, Pediatric Immunology, Meyer Children's Hospital, Florence, Italy.

Elisa De Vitis (E)

Department of Health Sciences, Section of Pediatrics, University of Florence, Florence, Italy.
Pediatric Clinic 2, Pediatric Immunology, Meyer Children's Hospital, Florence, Italy.

Arianna Casini (A)

Department of Health Sciences, Section of Pediatrics, University of Florence, Florence, Italy.

Giovanni Maria Poggi (GM)

Department of Health Sciences, Section of Pediatrics, University of Florence, Florence, Italy.
Department of Interdisciplinary Pediatrics, Section of Medical Pediatrics, Meyer Children's Hospital, Florence, Italy.

Giuseppe Indolfi (G)

Department of Interdisciplinary Pediatrics, Section of Medical Pediatrics, Meyer Children's Hospital, Florence, Italy.

Massimo Resti (M)

Department of Interdisciplinary Pediatrics, Section of Medical Pediatrics, Meyer Children's Hospital, Florence, Italy.

Chiara Azzari (C)

Department of Health Sciences, Section of Pediatrics, University of Florence, Florence, Italy.
Pediatric Clinic 2, Pediatric Immunology, Meyer Children's Hospital, Florence, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH